| Literature DB >> 34358446 |
Kathleen M Mulvaney1, Christa Blomquist1, Nischal Acharya1, Ruitong Li1, Matthew J Ranaghan2, Meghan O'Keefe2, Diego J Rodriguez1, Michael J Young1, Devishi Kesar1, Debjani Pal1, Matthew Stokes3, Alissa J Nelson3, Sidharth S Jain1, Annan Yang4, Zachary Mullin-Bernstein1, Josie Columbus1, Fazli K Bozal1, Adam Skepner2, Donald Raymond2, Salvatore LaRussa2, David C McKinney2, Yelena Freyzon1, Yossef Baidi1, Dale Porter5, Andrew J Aguirre6, Alessandra Ianari1, Brian McMillan7, William R Sellers8.
Abstract
PRMT5 is an essential arginine methyltransferase and a therapeutic target in MTAP-null cancers. PRMT5 uses adaptor proteins for substrate recruitment through a previously undefined mechanism. Here, we identify an evolutionarily conserved peptide sequence shared among the three known substrate adaptors (CLNS1A, RIOK1, and COPR5) and show that it is necessary and sufficient for interaction with PRMT5. We demonstrate that PRMT5 uses modular adaptor proteins containing a common binding motif for substrate recruitment, comparable with other enzyme classes such as kinases and E3 ligases. We structurally resolve the interface with PRMT5 and show via genetic perturbation that it is required for methylation of adaptor-recruited substrates including the spliceosome, histones, and ribosomal complexes. Furthermore, disruption of this site affects Sm spliceosome activity, leading to intron retention. Genetic disruption of the PRMT5-substrate adaptor interface impairs growth of MTAP-null tumor cells and is thus a site for development of therapeutic inhibitors of PRMT5.Entities:
Keywords: CDKN2A; COPR5; MTAP; PRMT5; RIOK1; Sm protein; arginine methylation; histone; pICln; splicing
Mesh:
Substances:
Year: 2021 PMID: 34358446 PMCID: PMC9016627 DOI: 10.1016/j.molcel.2021.07.019
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 19.328